longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

JIANGXI BIO

06915

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

JIANGXI BIO (06915)

Jiangxi Institute of Biological Products Inc. manufactures and exports biological products including Tetanus Antitoxin and Veterinary Medicine. The company offe...

Open
--
High
--
Low
--
Prev. Close
--
Volume
--
Turnover
--
Avg Price
--
Bid/Ask Ratio
--
Amplitude
--
52wk High
--
Volume Ratio
--
Turnover Ratio
--
52wk Low
--
HK Mkt Cap
--
Market Cap
--
P/ETTM
--
P/EDynamic
--
P/EStatic
--
EPSTTM
--
EPSDynamic
--
EPSStatic
--
BVPS
--
P/B
--
HK Shares
--
Dividend YieldTTM
--
DividendTTM
--
Shares
--
Min lot size
--
Currency
--

JIANGXI BIO Analyst Rating

View more

Forecast & Rating

Aug 19, 2026
Price forecast
HK$23.6059.78%
Forecast & RatingBuy
1analysts
  • Strong buy0.00%
  • Buy100.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%
Strong buy
0
Buy
1
Hold
0
Sell
0
Strong sell
0

Daily Events

  1. Jul, 3

    Jiangxi Bioproducts rebounded 1.1% to close at HK$6.37 after a volatile session, recovering from an intraday low of HK$6.02 triggered by a profit warning yesterday. The stock initially fell 26% following the warning but rallied on approval of an animal health product, which offset concerns about its Hong Kong listing sustainability. Despite the bounce, the stock trades 40.7% below its 52-week high of HK$10.75 and well below its 20-day moving average of HK$7.483, with a year-to-date decline of 34.9%, though its PE of 18.7x and PB of 3.56x are moderate for the sector.

News

  • Weekly Review · 2 days ago, 07:22 AM

    Weekly Recap | JIANGXI BIO -9.23%, consensus target above spot

  • Weekly Review · Sep 5 at 05:43 AM

    Weekly Recap | JIANGXI BIO -10.63%, interim profit falls 60.99%

  • Weekly Review · Aug 29 at 04:55 AM

    Weekly Recap | JIANGXI BIO +13.89%, consensus target above spot

  • Weekly Review · Aug 22 at 04:22 AM

    Weekly Recap | JIANGXI BIO +10.57%, new coverage flags antiserum platform pivot